CX-046684

DB19414ApprovedVaccines

CX-046684 is a COVID-19 mRNA vaccine encoding the pre-fusion stabilized Spike glycoprotein (S) of the SARS-CoV-2 Omicron variant lineage KP.2. It is the active ingredient of the 2024-2025 formulation of...

Primary indication: CX-046684, as the active ingredient in the 2024-2025 formulation of Spikevax, is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients ≥65 years...Curator reviewed · 2 structured indications
First approval: United States, 2024
Code names: CX-046684

Resolves to

Compound

UNIIKCK3ADW2DH

Clinical / RWD

RxNorm2691168

What you can answer from here — as of August 04, 2025

2Structured indicationsCondition, population, route and combination as fields, not prose

1ContraindicationEach with its own population and attribute set

3Marketed productsAcross 1 country and 1 labeller

1+ReferenceStructured and connected to the statements they support

Which other approved drugs treat the same conditions as CX-046684, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account